# US 6,730,783 B2 · Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,783 B2
- Document ID: US6730783B2
- Status: Granted
- Kind: B2
- Application number: 10/419,972
- Filed: 2003-04-22
- Published: 2004-01-01
- Granted: 2004-05-04
- Earliest claimed: 1996-11-26
- Assignees: 3-Dimensional Pharmaceuticals, Inc.
- Inventors: Bruce E. Tomczuk; Richard M. Soll; Tianbao Lu; Cynthia L. Fedde; Carl R. Illig; Thomas P. Markotan
- Web page: https://patentgrep.com/patent/US6730783B2

## CPC

- C07C 309/73: to carbon atoms of non-condensed six-membered aromatic rings
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07C 309/75: containing singly-bound oxygen atoms bound to the carbon skeleton
- C07C 309/76: containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C 309/77: containing carboxyl groups bound to the carbon skeleton
- C07C 311/16: having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C 311/17: to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C 311/18: to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C 311/19: to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C 311/21: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C 317/14: having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
- C07C 323/66: containing sulfur atoms of sulfo, esterified sulfo or halosulfonyl groups, bound to the carbon skeleton
- C07D 211/96: Sulfur atom
- C07D 213/42: having hetero atoms attached to the substituent nitrogen atom (nitro radicals C07D213/26)
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 215/36: Sulfur atoms (C07D215/24 takes precedence)
- C07D 217/02: with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D 217/22: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- C07D 295/13: to an acyclic saturated chain
- C07D 295/26: Sulfur atoms
- C07D 307/66: Nitrogen atoms
- C07C 2601/02: with a three-membered ring
- C07C 2601/14: The ring being saturated
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: wherein X is O or NR9 and R1-R4, R6-R9, R11, R12, Ra, Rb, Rc, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

## Claims

### Claim 1

A process for preparing an aminoguanidine or an alkoxyguanidine compound having the Formula I:
or a solvate, hydrate, prodrug, or pharmaceutically acceptable salt thereof, wherein:
R1 is one of aryl substituted by R13R14NSO2—, or heteroaryl, any of which may be optionally substituted;
R13 and R14 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heterocycle, heterocycloalkyl, carboxyalkyl, alkoxycarbonylalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, mono- and di-alkylaminoalkyl, provided that at least one of R13 and R14 is heterocycle or heterocycloalkyl, or R13 and R14 can be taken together with the nitrogen atom to which they are attached to form a three to seven membered ring, optionally containing one or more heteroatoms in addition to said nitrogen, such as oxygen, sulfur, or nitrogen (NR15), said ring being unsaturated or saturated, and said ring having one or two optional substituents, wherein said optional substituents and R15 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heterocycle, heterocycloalkyl, carboxyalkyl, alkoxycarbonylalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, mono- and di-alkylaminoalkyl, carboxy, alkoxycarbonyl, carboxamido, formyl, alkanoyl, aroyl, aralkanoyl, alkylsulfonyl, alkoxysulfonyl, sulfonamide, phosphonyl, phosphoramido, or phosphinyl;
Z is one of —NR10SO2—, —SO2NR10—, —NR10C(RyRz)—, —C(RyRz)NR10—, —OSO2—, —SO2O—, —OC(RyRz)—, —C(RyRz)O—, —NR10CO— or —CONR10—;
Ry and Rz are each independently one of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl or carboxy;
R2, R3 and R4 are each independently one of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, trifluoromethyl, halogen, hydroxyalkyl, cyano, nitro, carboxamido, —CO2Rx, —CH2ORx or —ORx, or when present on adjacent carbon atoms, R2 and R3 may also be taken together to form one of —CH═CH—CH═CH— or —(CH2)q—, where q is from 2 to 6, and R4 is defined as above;
Rx, in each instance, is independently one of hydrogen, alkyl or cycloalkyl wherein said alkyl or cycloalkyl groups may optionally have one or more unsaturations;
Y is one of —O—, —NR10—, —S—, —CHR10— or a covalent bond;
X is oxygen or NR9;
R9 is one of hydrogen, alkyl, cycloalkyl or aryl, wherein said alkyl, cycloalkyl or aryl can be optionally substituted with amino, monoalkylamino, dialkylamino, alkoxy, hydroxy, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, aryl, heteroaryl, acylamino, cyano or trifluoromethyl;
R6 is one of hydrogen, alkyl, aralkyl, aryl, hydroxyalkyl, aminoalkyl, monoalkylamino(C2-10)alkyl, dialkylamino(C2-10)alkyl or carboxyalkyl; or R6 and R12 are taken together to form —(CH2)w—, where w is 1-5;
R7 is one of hydrogen, alkyl, aralkyl, aryl, hydroxyalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, carboxyalkyl, hydroxy, alkoxy, aralkoxy, aryloxy, heteroaryloxy, or mono- or di-alkylamino, provided that n is other than zero when R7 is hydroxy, alkoxy, aralkoxy, aryloxy, heteroaryloxy, or mono- or di-alkylamino; R8, R11 and R12 are each independently one of hydrogen, alkyl, aralkyl, aryl, hydroxyalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl or carboxyalkyl; or R7 and R8 are taken together to form —(CH2)y, where y is zero (a bond), 1 or 2, while R11 and R12 are defined as above; or R7 and R12 are taken together to form —(CH2)q—, where q is zero (a bond), or 1 to 8, while R8 and R11 are defined as above; or R8 and R11 are taken together to form —(CH2)r—, where r is 2-8, while R7 and R12 are defined as above;
R10, in each instance, is independently one of hydrogen, alkyl, aralkyl, aryl, hydroxyalkyl, aminoalkyl, monoalkylamino(C2-10)alkyl, dialkylamino(C2-10)alkyl or carboxyalkyl;
Ra, Rb and Rc are independently hydrogen, alkyl, hydroxy, alkoxy, aryloxy, aralkoxy, alkoxycarbonyloxy, cyano or —CO2Rw;
Rw is alkyl, cycloalkyl, phenyl, benzyl,
where Rd and Re are independently hydrogen, C1-6 alkyl, C2-6 alkenyl or phenyl, Rf is hydrogen, C1-6 alkyl, C2-6 alkenyl or phenyl, Rg is hydrogen, C1-6 alkyl, C2-6 alkenyl or phenyl, and Rh is aralkyl or C1-6 alkyl;
n is from zero to 8; and m is from zero to 4, comprising
(a) reacting an aminoguanidine of the formula
wherein R6, Ra, Rb and Rc are as defined above, with a carbonyl-containing compound of the formula
wherein R1-R4, Z, Y, n, m, R7, R8, R11 and R12 are as defined above to form an amidinohydrazone, and thereafter selectively reducing the hydrazone carbon to nitrogen double bond of the amidinohydrazone; or
(b) reacting an alkoxyamine compound of the formula
wherein R1-R4, Z, Y, n, m, R7, R8, R11 and R12 are as defined above, with a guanidinylating reagent.

### Claim 2 (depends on 1)

The process of claim 1, comprising reacting an aminoguanidine of the formula
wherein R6, Ra, Rb and Rc are as defined above, with a carbonyl-containing compound of the formula
wherein R1-R4, Z, Y, n, m, R7, R8, R11 and R12 are as defined above to form an amidinohydrazone, and thereafter selectively reducing the hydrazone carbon to nitrogen double bond of the amidinohydrazone.

### Claim 3 (depends on 2)

The process of claim 2, wherein the aminoguanidine of Formula VII is provided as a hydrochloride, acetate or nitrate salt.

### Claim 4 (depends on 2)

The process of claim 2, wherein the reaction is conducted at ambient temperature using an alcohol as a solvent.

### Claim 5 (depends on 2)

The process of claim 2, wherein an acid is added to the reaction mixture.

### Claim 6 (depends on 1)

The process of claim 1, comprising reacting an alkoxyamine compound of the formula
wherein R1-R4, Z, Y, n, m, R7, R8, R11 and R12 are as defined above, with a guanidinylating reagent.

### Claim 7 (depends on 6)

The process of claim 6, wherein said guanidinylating reagent is aminoiminosulfonic acid, optionally substituted 1H-pyrazole-1-carboxamidines, or N,N′-bis(tert-butoxycarbonyl) S-methyl isothiourea.

### Claim 8 (depends on 1)

The process of claim 1, wherein R1 is C6-14 aryl, which is substituted with R13R14NSO2— and optionally substituted by one moiety selected from the group consisting of alkyl, hydroxy, nitro, trifluoromethyl, halogen, alkoxy, aminoalkoxy, aminoalkyl, hydroxyalkyl, hydroxyalkoxy, cyano, aryl, amino, monoalkylamino, dialkylamino, carboxy, carboxyalkyl, carboxyalkoxy, mono(hydroxyalkyl)amino, bis(hydroxyalkyl)amino, mono(carboxyalkyl)amino, bis(carboxyalkyl)amino, alkoxycarbonylamino, alkoxycarbonyl, aralkoxycarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, aralkylsulfonyl, alkylsulfinyl, alkylsulfonamido, arylsulfonamido, aralkylsulfonamido, amidino, guanidino, alkyliminoamino, formyliminoamino, trifluoromethoxy, perfluoroethoxy and R13R14NSO2—, where
R13 and R14 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heterocycle, heterocycloalkyl, carboxyalkyl, alkoxycarbonylalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, mono- and di-alkylaminoalkyl, provided that at least one of R13 and R14 is heterocycle or heterocycloalkyl, or R13 and R14 can be taken together with the nitrogen atom to which they are attached to form a three to seven membered ring, optionally containing one or more heteroatoms in addition to said nitrogen, such as oxygen, sulfur, or nitrogen (NR15), said ring being unsaturated or saturated, and said ring having one or two optional substituents, wherein said optional substituents and R15 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heterocycle, heterocycloalkyl, carboxyalkyl, alkoxycarbonylalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, mono- and di-alkylaminoalkyl, carboxy, alkoxycarbonyl, carboxamido, formyl, alkanoyl, aroyl, aralkanoyl, alkylsulfonyl, alkoxysulfonyl, sulfonamido, phosphonyl, phosphoramido, or phosphinyl.

### Claim 9 (depends on 1)

The process of claim 1, wherein R1 is heteroaryl, optionally substituted by one or more of hydroxy, nitro, trifluoromethyl, halogen, C1-6 alkoxy, C1-6 alkyl, amino, mono(C1-6)alkylamino, di(C1-6)alkylamino, cyano, amidino, guanidino, carboxyalkoxy, trifluoromethoxy or perfluoroethoxy.

### Claim 10 (depends on 1)

The process of claim 1, wherein R1 is pyridyl, pyrazolyl, thienyl, chromenyl, benzoxazolyl, benzthiadiazolyl, quinazolinyl, quinolinyl, isoquinolinyl or tetrahydroquinolinyl, any of which is optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, nitro, trifluoromethyl, halogen, C1-6 alkoxy, C1-6 alkyl, amino, mono(C1-6)alkylamino, di(C1-6)alkylamino, cyano, amidino, guanidino, carboxyalkoxy, trifluoromethoxy and perfluoroethoxy.

### Claim 11 (depends on 1)

The process of claim 1, wherein Y is one of —O—, —NR10— or a covalent bond, and R10in each instance is one of hydrogen, C1-6 alkyl, benzyl, phenethyl, C2-10 hydroxyalkyl or C2-7 carboxyalkyl.

### Claim 12 (depends on 11)

The process of claim 11, wherein Y is —O—.

### Claim 13 (depends on 1)

The process of claims 1, wherein Z is —SO2NR10—, —SO2O— or —CH2O—.

### Claim 14 (depends on 1)

The process of claim 1, wherein Ra, Rb and Rc are hydrogen.

### Claim 15 (depends on 1)

The process of claim 1, wherein R7 and R8 and R11 and R12 are independently hydrogen, C1-6 alkyl, C6-10 ar(C1-6)alkyl, C6-10 aryl, C2-10 hydroxyalkyl or C2-10 carboxyalkyl.

### Claim 16 (depends on 1)

The process of claim 1, wherein R7 and R8 are taken together to form —(CH2)y—, and y is 0, 1 or 2.

### Claim 17 (depends on 1)

The process of claim 1, wherein n is from 1 to 4.

### Claim 18 (depends on 1)

The process of claim 1, wherein m is zero, 1, 2 or 3.

### Claim 19 (depends on 1)

The process of claim 1, wherein m and n are each zero and R7, R8, R11 and R12 are each hydrogen.

### Claim 20 (depends on 1)

The process of claim 1, wherein R2 and R4 are hydrogen and R3 is methyl.

### Claim 21 (depends on 1)

The process of claim 1, wherein:
R1 is one of C6-10 aryl substituted by R13R14NSO2—, pyridinyl, thienyl, quinazolinyl, quinolinyl or tetrahydroquinolinyl, any of which is optionally substituted by one or two of hydroxy, nitro, trifluoromethyl, halogen, C1-6 alkyl, C6-10 aryl, C1-6 alkoxy, C6-10 ar(C1-6)alkoxy, C1-6 aminoalkyl, C1-6 aminoalkoxy, amino, mono(C1-4)alkylamino, di(C1-4)alkylamino, C2-6 alkoxycarbonylamino, C2-6 alkoxycarbonyl, carboxy, C1-6 hydroxyalkyl, C2-6 hydroxyalkoxy, (C1-6)alkoxy(C2-6)alkoxy, mono- and di-C1-4 alkylamino(C2-6)alkoxy, C2-10 mono(carboxyalkyl)amino, bis(C2-10 carboxyalkyl)amino, C6-14 ar(C1-6)alkoxycarbonyl, C2-6 alkynylcarbonyl, C1-6 alkylsulfonyl, C2-6 alkenylsulfonl, C2-6 alkynylsulfonyl, C6-10 arylsulfonyl, C6-10 ar(C1-6)alkylsulfonyl, C1-6 alkylsulfinyl, C1-6 alkylsulfonamido, C6-10 arylsulfonamido, C6-10 ar(C1-6)alkylsulfonamido, amidino, guanidino, C1-6 alkyliminoamino, formyliminoamino, C2-6 carboxyalkoxy, C2-6 carboxyalkyl, carboxyalkylamino, cyano, trifluoromethoxy, perfluoroethoxy and R13R14NSO2—;
R13 and R14 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heterocycle, heterocycloalkyl, carboxyalkyl, alkoxycarbonylalkyl, cyano(C2-10)alkyl, hydroxy(C2-10)alkyl, alkoxy(C2-10)alkyl, mono- and di-alkylamino(C2-10)alkyl provided that when R1 is C6-10 aryl, at least one of R13 and R14 is heterocycle or heterocycloalkyl, or R13 and R14 can be taken together with the nitrogen atom to which they are attached to form a three to seven membered ring, optionally containing one or more heteroatoms in addition to said nitrogen, such as oxygen, sulfur, or nitrogen (NR15), said ring being unsaturated or saturated, and said ring having one or two optional substituents, wherein said optional substituents are selected from the group consisting of hydroxy, acyloxy, alkoxy, aryloxy, amino, mono- and di-alkylamino, acylamino, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heterocycle, heterocycloalkyl, carboxyalkyl, alkoxycarbonylalkyl, cyano(C2-10)alkyl, hydroxy(C2-10)alkyl, alkoxy(C2-10)alkyl, mono- and di-alkylamino(C2-10)alkyl, carboxy, alkoxycarbonyl, carboxamido, formyl, alkanoyl, aroyl, aralkanoyl, alkylsulfonyl, alkoxysulfonyl, sulfonamido, phospbonyl, phosphoramido, and phosphinyl, and R15 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heterocycle, heterocycloalkyl, carboxyalkyl, alkoxycarbonylalkyl, cyano(C2-10)alkyl, hydroxy(C2-10)alkyl, alkoxy(C2-10)alkyl, mono- and di-alkylamino(C2-10)alkyl, carboxy, alkoxycarbonyl, carboxamido, formyl, alkanoyl, aroyl, aralkanoyl, alkylsulfonyl, alkoxysulfonyl, sulfonamido, phosphonyl, phosphoramido, and phosphinyl;
Z is one of —SO2O—, —SO2NR10—, —C(RyRz)O— or —OC(RyRz)—, where Ry and Rz are each hydrogen;
R2, R3 and R4 are independently one of hydrogen, C1-4 alkyl, C3-8 cycloalkyl, phenyl, benzyl, trifluoromethyl, halogen, hydroxy(C1-4)alkyl, cyano, nitro, carboxamido, carboxy, C1-4 alkoxycarbonyl, C1-4 alkoxymethyl or C1-4 alkoxy; or alternatively, R2 and R3, when present on adjacent carbon atoms, may also be taken together to form one of —CH═CH—CH═CH— or —(CH2)q—, where q is from 2 to 6, and R4 is as defined above;
Y is one of —O—, —S—, —NR10—, or a covalent bond;
Ra, Rb and Rc are each one of hydrogen, C1-4 alkyl, hydroxy, C1-4 alkoxy, phenoxy, C1-4 alkyloxycarbonyl, benzyloxycarbonyl, cyano,
where Rh is benzyl, methyl, ethyl, isopropyl, sec-butyl or t-butyl, and where Rf is hydrogen or C1-6 alkyl;
R6 is one of hydrogen, C1-6 alkyl, C6-10 ar(C1-6)alkyl, C6-10 aryl, C2-10 hydroxyalkyl, C2-10 aminoalkyl, mono(C1-4)alkylamino(C2-8)alkyl, di(C1-4)alkylamino(C2-8)alkyl or C2-10 carboxyalkyl;
R7, R8, R11 and R12 are independently one of hydrogen, C1-6 alkyl, C2-10 carboxyalkyl or C2-10 hydroxyalkyl, or R7 and R8are taken together to form —(CH2)y— where y is zero, 1 or 2, while R11 and R12 are defined as above; or R7 and R12 are taken together to form —(CH2)q—, where q is zero (a bond), or 1, 2 or 3, while R8 and R11 are defined as above; or R8 and R11 are taken together to form —(CH2)r—, where r is 2, 3, or 4, while R7 and R12 are defined as above;
R9 is hydrogen, or C1-10 alkyl, optionally substituted with amino, mono(C1-4)alkylamino, C1-6 alkoxy, hydroxy, carboxy, phenyl, C1-4 alkyloxycarbonyl, C6-10 ar(C1-4)alkoxycarbonyl, C1-6 acylamino, cyano or trifluoromethyl;
R10, in each instance, is independently hydrogen, C1-6 alkyl, benzyl, phenyl, C2-10 hydroxyalkyl, C2-10 aminoalkyl, C1-4 monoalkylamino(C2-8)alkyl, C1-4 dialkylamino-(C2-8)alkyl or C2-10 carboxyalkyl;
n is from zero to 8; and m is from zero to 4.

### Claim 22 (depends on 1)

The process of claim 1, wherein:
R1 is one of pyridyl, thienyl, quinolinyl or isoquinolinyl, optionally substituted by one or two of chloro, methoxy, methyl, trifluoromethyl, cyano, nitro, amino or dimethylamino;
Z is one of —SO2O—, —SO2NR10—, —CH2O— or —OCH2—;
R2 and R3 are hydrogen or C1-4 alkyl, or R2 and R3 may also be taken together to form —CH═CH—CH═CH—;
R4is one of hydrogen, methyl, methoxy or trifluoromethyl;
Y is one of O, NR10 or a covalent bond;
Ra, Rb and Rc are hydrogen, hydroxy,
where Rh is benzyl or t-butyl, and where Rf is hydrogen or methyl;
R6 is hydrogen, C1-4 alkyl, C2-4 hydroxyalkyl, C2-4 carboxyalkyl, C2-4 aminoalkyl, dimethylamino(C2-8)alkyl, or methylamino(C2-8)alkyl;
R7, R8, R11 and R12 are independently one of hydrogen, C1-6 alkyl, C2-10 hydroxyalkyl or C2-10 carboxyalkyl, or R7 and R8are taken together to form —(CH2)y— where y is zero, 1 or 2, while R11 and R12 are defined as above; or R7 and R12 are taken together to form —(CH2)q—, where q is zero (a bond), or 1, 2 or 3, while R8 and R11 are defined as above; or R8 and R11 are taken together to form —(CH2)r—, where r is 2, 3 or 4, while R7 and R12 are defined as above;
R9 is hydrogen or C1-4 alkyl;
R10, in each instance, is independently hydrogen, C1-4 alkyl, C2-4 hydroxyalkyl, C2-4 carboxyalkyl, C2-4 aminoalkyl, dimethylamino(C2-8)alkyl, methylamino(C2-8)alkyl;
n is from zero to 4; and m is zero, 1, 2 or 3.

### Claim 23 (depends on 1)

The process of claim 1, wherein:
R1 is phenyl, substituted by R13R14NSO2—, where
R13 and R14 are independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C6-10 ar(C1-4)alkyl, pyridyl, pyridyl(C1-4)alkyl, carboxy(C1-6)alkyl, C1-4 alkoxycarbonyl(C1-4)alkyl, cyano(C2-6)alkyl, hydroxy(C2-6)alkyl, C1-4 alkoxy(C2-6)alkyl, mono- and di-(C1-4)alkylamino(C2-6)alkyl provided that at least one of R13 or R14 is pyridyl or pyridyl(C1-4)alkyl, or R13 and R14 can be taken together with the nitrogen atom to which they are attached to form a heterocyclic ring selected from the group consisting of N-morpholino, N-piperazinyl (optionally N′ substituted with C1-6 alkyl, C1-6 hydroxyalkyl, C6-10 aryl, C6-10 aryl(C1-6)alkyl, C1-6 alkylsulfonyl, C6-10 arylsulfonyl, C1-6 alkylcarbonyl, morpholino or C6-10 arylcarbonyl), N-pyrrolyl, N-piperidinyl, N-pyrrolidinyl, N-dihydropyridyl, and N-indolyl, wherein said heterocyclic ring can be optionally substituted with one or two of hydroxy, C1-8 alkanoyloxy, C1-6 alkoxy, C6-10 aryloxy, amino, mono- and di-(C1-6)alkylamino, C1-8 alkanoylamino, C1-4 alkyl, C3-7 cycloalkyl, C6-10 aryl, C6-10 ar(C1-4)alkyl, heterocycle, heterocycloalkyl, carboxy(C1-6)alkyl, C1-4 alkoxycarbonyl(C1-4)alkyl, cyano(C2-6)alkyl, hydroxy(C2-6)alkyl, C1-4 alkoxy(C2-6)alkyl, mono- and di-(C1-4)alkylamino(C2-6)alkyl, carboxy, C1-6 alkoxycarbonyl, carboxamido, formyl, C1-6 alkanoyl, C6-10 aroyl, C6-10 ar(C1-4)alkanoyl, C1-6 alkylsulfonyl, C1-6 alkoxysulfonyl, sulfonamido, phosphonyl, phosphoramido, or phosphinyl;
Z is one of —SO2O—, —SO2NR10—, —CH2O— or —OCH2—;
R2 and R3 are hydrogen or C1-4 alkyl, or R2 and R3 may also be taken together to form —CH═CH—CH═CH—;
R4 is one of hydrogen, methyl, methoxy or trifluoromethyl;
Y is one of O, NR10 or a covalent bond;
Ra, Rb and Rc are hydrogen, hydroxy,
where Rh is benzyl or t-butyl, and where Rf is hydrogen or methyl;
R6 is hydrogen, C1-4 alkyl, C2-4 hydroxyalkyl, C2-4 carboxyalkyl, C2-4 aminoalkyl, dimethylamino(C2-8)alkyl, or methylamino(C2-8)alkyl;
R7, R8, R11 and R12 are independently one of hydrogen, C1-6 alkyl, C2-10 hydroxyalkyl or C2-10 carboxyalkyl, or R7 and R8 are taken together to form —(CH2)y— where y is zero, 1 or 2, while R11 and R12 are defined as above; or R7 and R12 are taken together to form —(CH2)q—, where q is zero (a bond), or 1, 2 or 3, while R8 and R11 are defined as above; or R8 and R11 are taken together to form —(CH2)r—, where r is 2, 3 or 4, while R7 and R12 are defined as above;
R9 is hydrogen or C1-4 alkyl;
R10, in each instance, is independently hydrogen, C1-4 alkyl, C2-4 hydroxyalkyl, C2-4 carboxyalkyl, C2-4 aminoalkyl, dimethylamino(C2-8)alkyl, methylamino(C2-8)alkyl;
n is from zero to 4; and m is zero, 1, 2 or 3.

### Claim 24 (depends on 1)

The process of claim 1, wherein the moiety —Z—R1 is attached to the benzene ring in a position meta- to Y.

### Claim 25 (depends on 1)

The process of claim 1, wherein the compound having the following formula is prepared:
or a solvate, hydrate, pharmaceutically acceptable salt or prodrug thereof: wherein
R21 is one of phenyl, thienyl, quinolinyl or isoquinolinyl, optionally substituted by one or two substituents independently selected from the group consisting of halogen, C1-4 alkyl, C1-4 alkoxy, methoxy, trifluoromethyl, cyano, nitro, amino or dimethylamino; and when R21 is phenyl, said phenyl is substituted by R22R23NSO2—, where R22 and R23 are independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C6-10 ar(C1-4)alkyl, pyridyl, pyridyl(C1-4)alkyl, carboxy(C1-6)alkyl, C1-4 alkoxycarbonyl(C1-4)alkyl, cyano(C2-6)alkyl, hydroxy(C2-6)alkyl, C1-4 alkoxy(C2-6)alkyl, mono- and di-(C1-4)alkylamino(C2-6)alkyl provided that at least one of R22 or R23 is pyridyl or pyridyl(C1-4)alkyl, or R22 and R23 can be taken together with the nitrogen atom to which they are attached to form a heterocyclic ring selected from the group consisting of N-morpholino, N-piperazinyl (optionally N′ substituted with C1-6 alkyl, C1-6 hydroxyalkyl, C6-10 aryl, C6-10 aryl(C1-6)alkyl, C1-6 alkylsulfonyl, C6-10 arylsulfonyl, C1-6 alkylcarbonyl, morpholino or C6-10 arylcarbonyl), N-pyrrolyl, N-piperidinyl, N-pyrrolidinyl, N-dihydropyridyl, and N-indolyl, wherein said heterocyclic ring can be optionally substituted with one or two of hydroxy, C1-8 alkanoyloxy, C1-6 alkoxy, C6-10 aryloxy, amino, mono- and di-(C1-6)alkylamino, C1-8 alkanoylamino, C1-4 alkyl, C3-7 cycloalkyl, C6-10 aryl, C6-10 ar(C1-4)alkyl, heterocycle, heterocycloalkyl, carboxy(C1-6)alkyl, C1-4 alkoxycarbonyl(C1-4)alkyl, cyano(C2-6)alkyl, hydroxy(C2-6)alkyl, C1-4 alkoxy(C2-6)alkyl, mono- and di-(C1-4)alkylamino(C2-6)alkyl, carboxy, C1-6 alkoxycarbonyl, carboxamido, formyl, C1-6 alkanoyl, C6-10 aroyl, C6-10 ar(C1-4)alkanoyl, C1-6 alkylsulfonyl, C1-6 alkoxysulfonyl, sulfonamido, phosphonyl, phosphoramido, or phosphinyl;
R24 is hydrogen or C1-4 alkyl;
Y′ is one of O, NR10 or a covalent bond, wherein R10 is hydrogen, C1-6 alkyl, C6-10 ar(C1-6)alkyl, C6-10 aryl, C2-10 hydroxyalkyl, C2-10 aminoalkyl, C2-7 carboxyalkyl, mono(C1-4 alkyl)amino(C1-8)alkyl, and di(C1-4 alkyl)amino(C1-8)alkyl; and
a is 1 or 2;
X′ is O or NR29; and
R29 is hydrogen or C1-4 alkyl.

### Claim 26 (depends on 25)

The process of claim 25, wherein:
R24 is methyl; Y′ is O; a is one; and X′ is O or NH.

### Claim 27 (depends on 1)

The process of claim 1, wherein the compound having the following formula is prepared:
or a solvate, hydrate, pharmaceutically acceptable salt or prodrug thereof; wherein
R21 is one of phenyl, thienyl, quinolinyl or isoquinolinyl, optionally substituted by one or two substituents independently selected from the group consisting of halogen, C1-4 alkyl, C1-4 alkoxy, methoxy, trifluoromethyl, cyano, nitro, amino or dimethylamino; and when R21 is phenyl, said phenyl is substituted by R22R23NSO2—, where R22 and R23 are independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C6-10 ar(C1-4)alkyl, pyridyl, pyridyl(C1-4)alkyl, carboxy(C1-6)alkyl, C1-4 alkoxycarbonyl(C1-4)alkyl, cyano(C2-6)alkyl, hydroxy(C2-6)alkyl, C1-4 alkoxy(C2-6)alkyl, mono- and di-(C1-4)alkylamino(C2-6)alkyl provided that at least one of R22 or R23 is pyridyl or pyridyl(C1-4)alkyl, or R22 and R23 can be taken together with the nitrogen atom to which they are attached to form a heterocyclic ring selected from the group consisting of N-morpholino, N-piperazinyl (optionally N′ substituted with C1-6 alkyl, C1-6 hydroxyalkyl, C6-10 aryl, C6-10 aryl(C1-6)alkyl, C1-6 alkylsulfonyl, C6-10 arylsulfonyl, C1-6 alkylcarbonyl, morpholino or C6-10 arylcarbonyl), N-pyrrolyl, N-piperidinyl, N-pyrrolidinyl, N-dihydropyridyl, and N-indolyl, wherein said heterocyclic ring can be optionally substituted with one or two of hydroxy, C1-8 alkanoyloxy, C1-6 alkoxy, C6-10 aryloxy, amino, mono- and di-(C1-6)alkylamino, C1-8 alkanoylamino, C1-4 alkyl, C3-7 cycloalkyl, C6-10 aryl, C6-10 ar(C1-4)alkyl, heterocycle, heterocycloalkyl, carboxy(C1-6)alkyl, C1-4 alkoxycarbonyl(C1-4)alkyl, cyano(C2-6)alkyl, hydroxy(C2-6)alkyl, C1-4 alkoxy(C2-6)alkyl, mono- and di-(C1-4)alkylamino(C2-6)alkyl, carboxy, C1-6 alkoxycarbonyl, carboxamido, formyl, C1-6 alkanoyl, C6-10 aroyl, C6-10 ar(C1-4)alkanoyl, C1-6 alkylsulfonyl, C1-6 alkoxysulfonyl, sulfonamido, phosphonyl, phosphoramido, or phosphinyl;
R24 is hydrogen or C1-4 alkyl;
X′ is O or NR29; and
R29 is hydrogen or C1-4 alkyl;
Y′ is one of O, NR10 or a covalent bond, wherein R10is hydrogen, C1-6 alkyl, C6-10 ar(C1-6)alkyl, C6-10 aryl, C2-10 hydroxyalkyl C2-10 aminoalkyl, C2-7 carboxyalkyl, mono(C1-4 alkyl)amino(C1-8)alkyl, and di(C1-4 alkyl)amino(C1-8)alkyl; and
b is 1 or 2.

### Claim 28 (depends on 1)

The process of claim 1, wherein Z is —NR10CO—.

### Claim 29 (depends on 1)

The process of claim 1, wherein the compound prepared is one of
3-[5-methyl-3-(quinolinyl-8-sulfonyloxy)phenoxy]propoxyguanidine;
3-[3-(5-isoquinolinylsulfonyloxy)-5-methylphenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(4-morpholinylsulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(4-ethyloxycarbonylpiperidin-1-ylsulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(4-carboxylpiperidin-1-ylsulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(3-methylquinolinyl-8-sulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(4-methylsulfonylpiperazin-1-ylsulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(4-(2-pyrimidinyl)piperazin-1-ylsulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(N-ethyl-N-(4-pyridylmethyl)aminosulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(4-ethylpiperazin-1-ylsulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(N-(2-cyanoethyl)-N-(3-pyridylmethyl)aminosulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(N-(ethoxycarbonylmethyl)-N-(2-pyridylmethyl)aminosulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(4-(ethoxycarbonylmethyl)piperazin-1-ylsulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(4-(carboxymethyl)piperazin-1-ylsulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(4-(2-pyridyl)piperazinylsulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(4-phenylpiperazinylsulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(4-benzylpiperazinylsulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(4-(2-methoxyphenyl)piperazinylsulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(N-(2-cyanoethyl)-N-(2-furanylmethyl)aminosulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(4-methylpiperazinylsulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(N-methyl-N-(3-pyridylmethyl)aminosulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(2-(4-morpholinyl)ethylaminosulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(4-ethoxycarbonyl-1-piperazinylsulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(4-pyridylmethylaminosulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
or a hydrochloride or acetate salt thereof.

### Claim 30 (depends on 1)

The process of claim 1, wherein the compound 3-[5-methyl-3-(quinolinyl-8-sulfonyloxy)phenoxy]propoxyguanidine or a solvate, a hydrate, or a pharmaceutically acceptable salt thereof is prepared.

### Claim 31 (depends on 30)

The process of claim 30, wherein the compound 3-[5-methyl-3-(quinolinyl-8-sulfonyloxy)phenoxy]propoxyguanidine hydrochloride is prepared.

### Claim 32 (depends on 1)

The process of claim 1, wherein the compound prepared is one of
3-[3-(5-chlorothiophenyl-2-sulfonyloxy)-5-methylphenoxy]propoxyguanidine;
3-[5-methyl-3-(1,2,3,4-tetrahydroquinolinyl-8-sulfonyloxy)phenoxy]propoxyguanidine;
3-[5-hydroxymethyl-3-(quinolinyl-8-sulfonyloxy)phenoxy]propoxyguanidine;
1-[[5-methyl-3-(quinolinyl-8-sulfonyloxy)phenoxy]methyl]cyclopropylmethoxyguanidine;
3-[5-methyl-3-(2-(acetylpiperazinylsulfonyl)phenylsulfonyloxy)phenoxy]propoxygyanidine;
3-(3-(6-(2,3-dihydro-1,1-dioxobenzo[b]thiophene)sulfonyloxy)-5-methylphenoxy)propoxy]guanidine trifluoroacetate;
3-[5-methyl-3-(N-ethyl-3,4-(methylenedioxy)anilinosulfonylphenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-((3-ethoxycarbonyl-1-piperidinosulfonyl)phenylsulfonyloxy)-phenoxy]propoxyguanidine;
3-[5-methyl-3-((3-carboxypiperidinosulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-((2-methoxycarbonyl-1-pyrrolidinosulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(2-carboxy-1-pyrrolidinosulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(N-methyl-N-(2-(2-pyridyl)ethyl)aminosulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(N-propyl-N-(2-(2-pyridyl)ethyl)aminosulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(4-(piperidin-1-yl)piperidin-1-ylsulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(N-methyl-N-(2-(4-pyridyl)ethyl)aminosulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(N-methyl-N-(1-methyl-4-piperidinyl)aminosulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[5-methyl-3-(2-(4-(pyrrolidin-1-yl)piperidin-1-ylsulfonyl)phenylsulfonyloxy)phenoxy]propoxyguanidine;
3-[3-(5-chlorothiophenyl-2-sulfonyloxy)-5-methylphenoxy]propylaminoguanidine;
or a hydrochloride or acetate salt thereof.

### Claim 33

The process for preparing a compound having the Formula I:
or a solvate, hydrate, prodrug, or pharmaceutically acceptable salt thereof; wherein:
R1 is one of alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl or heteroaryl, any of which may be optionally substituted;
Z is one of —NR10SO2—, —SO2NR10—, —NR10C(RyRz)—, —C(RyRz)NR10—, —OSO2—, —SO2O—, —OC(RyRz)—, —C(RyRz)O—, —NR10CO— or —CONR10—;
Ry and Rz are each independently one of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl or carboxy;
R2, R3 and R4 are each independently one of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, trifluoromethyl, halogen, hydroxyalkyl, cyano, nitro, carboxamido, —CO2Rx, —CH2ORx or —ORx, or when present on adjacent carbon atoms, R2 and R3 may also be taken together to form one of —CH═CH—CH═CH— or —(CH2)q—, where q is from 2 to 6, and R4 is defined as above;
Rx, in each instance, is independently one of hydrogen, alkyl or cycloalkyl wherein said alkyl or cycloalkyl groups may optionally have one or more unsaturations;
Y is one of —O—, —NR10—, —S—, —CHR10— or a covalent bond;
R10, in each instance, is independently one of hydrogen, alkyl, aralkyl, aryl, hydroxyalkyl, aminoalkyl, monoalkylamino(C2-10)alkyl, dialkylamino(C2-10)alkyl or carboxyalkyl;
Rw is alkyl, cycloalkyl, phenyl, benzyl,
where Rd and Rc are independently hydrogen, C1-6 alkyl, C2-6 alkenyl or phenyl, Rf is hydrogen, C1-6 alkyl, C2-6 alkenyl or phenyl, Rg is hydrogen, C1-6 alkyl, C2-6 alkenyl or phenyl, and Rh is aralkyl or C1-6 alkyl; and:
C. R6 and Rb are taken together to form —CH2—(CH2)r—, where r is 1, 2 or 3; Ra is hydrogen or hydroxy;
Rc is hydrogen, alkyl, hydroxy, alkoxy, aryloxy, aralkoxy, alkoxycarbamoyloxy, cyano or —CO2Rw, where Rw is as defined above; R7, R8, R11 and R12 are each independently one of hydrogen, alkyl, aralkyl, aryl, hydroxyalkyl or carboxyalkyl, or R7 and R8 are taken together to form —(CH2)y—, where y is zero, 1 or 2; or
D. Ra and Rc are taken together to form —CH2—(CH2)s—, where s is 1 or 2; and Rb is hydrogen, alkyl, alkoxy, aryloxy, aralkoxy, alkoxycarbonyloxy, cyano or —CO2Rw, where Rw is as defined above; R6 is hydrogen, C1-4 alkyl, C2-4 hydroxyalkyl, C2-4 carboxyalkyl, C2-4 aminoalkyl, dimethylamino(C2-8)alkyl, or methylamino(C2-8)alkyl; R7, R8, R11 and R12 are each independently one of hydrogen, alkyl, aralkyl, aryl, hydroxyalkyl or carboxyalkyl, or R7 and R8 are taken together to form —(CH2)y—, where y is zero, 1 or 2; comprising
(a) reacting an aminoguanidine of the formula
wherein R6, Ra, Rb and Rc are as defined above, with a carbonyl-containing compound of the formula
wherein R1-R4, Z, Y, n, m, R7, R8, R11 and R12 are as defined above to form an amidinohydrazone, and thereafter selectively reducing the hydrazone carbon to nitrogen double bond of the amidinohydrazone; or
(b) reacting an alkoxyamine compound of the formula
wherein R1-R4, Z, Y, n, m, R7, R8, R11 and R12 are as defined above, with a guanidinylating reagent.

### Claim 34 (depends on 33)

The process of claim 33, comprising reacting an aminoguanidine of the formula
wherein R6, Ra, Rb and Rc are as defined above, with a carbonyl-containing compound of the formula
wherein R1-R4, Z, Y, n, m, R7, R8, R11 and R12 are as defined above to form an amidinohydrazone, and thereafter selectively reducing the hydrazone carbon to nitrogen double bond of the amidinohydrazone.

### Claim 35 (depends on 34)

The process of claim 34, wherein the aminoguanidine of Formula VII is provided as a hydrochloride, acetate or nitrate salt.

### Claim 36 (depends on 34)

The process of claim 34, wherein the reaction is conducted at ambient temperature using an alcohol as a solvent.

### Claim 37 (depends on 34)

The process of claim 34, wherein an acid is added to the reaction mixture.

### Claim 38 (depends on 33)

The process of claim 33, comprising reacting an alkoxyamine compound of the formula
wherein R1-R4, Z, Y, n, m, R7, R8, R11 and R12 are as defined above, with a guanidinylating reagent.

### Claim 39 (depends on 38)

The process of claim 38, wherein said guanidinylating reagent is aminoiminosulfonic acid, optionally substituted 1H-pyrazole-1-carboxamidines, or N,N′-bis(tert-butoxycarbonyl) S-methyl isothiourea.
